Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: A Continued Need for Ovarian Cancer Patients
Conclusions:
This docetaxel-based IP chemotherapy regimen demonstrates an improved tolerability profile compared with GOG172. Additional evaluations on alternative IP regimens remain warranted. Short follow-up time limits survival assessment, but results are encouraging.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Gynecologic Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Docetaxel | Epithelial Cancer | Fallopian Tube Cancer | Gastroenterology | Ovarian Cancer | Ovaries | Study | Taxotere | Toxicology